Huberman LabDr. Kyle Gillett on Huberman Lab: Why lifestyle beats TRT
Sleep, diet, and exercise optimize hormones before any drug is needed; Gillett covers testosterone thresholds, TRT trade-offs, and DHEA for both sexes.
CHAPTERS
- 0:00 – 1:48
How clinicians assess hormone health: symptoms, history & getting labs ordered
Huberman and Dr. Kyle Gillett open by outlining how a hormone-focused intake works: pairing physical exam findings with family and social history, then translating subjective complaints into clinically actionable lab work. They emphasize that “not feeling like you used to” (energy, focus, performance, libido) can be a valid reason to test—even without obvious disease.
- •Use family/social history to infer genetic and lifestyle drivers of hormone patterns
- •Compare current functioning to earlier decades (e.g., 50 vs 20) to surface meaningful changes
- •Specific symptoms (energy, focus, athletic performance, libido) help justify a more complete lab panel
- •You don’t need a clear pathology for testing—relevant symptoms can be sufficient
- 1:48 – 2:47
Women vs. men: different barriers and signals for hormone evaluation
They contrast hormone assessment challenges across sexes. Women often have more obvious, trackable physiological signals (cycle regularity, bleeding patterns), while men may be reluctant to report symptoms tied to libido or vitality despite wanting testosterone data.
- •Menstrual regularity and bleeding changes provide objective signals in women
- •Men commonly want testosterone testing but hesitate to discuss libido/energy concerns
- •Cultural stigma can reduce men’s reporting of hypogonadal symptoms
- •Better symptom reporting enables better diagnostic precision
- 2:47 – 4:32
The “Big 6” lifestyle pillars for hormone optimization
Dr. Gillett lays out a long-horizon approach: small, consistent lifestyle improvements beat short bursts of extreme intervention. He frames hormone health around six pillars, highlighting diet and resistance training as the most powerful levers, then adds stress, sleep, sunlight/outdoors, and spirit.
- •Diminishing returns: consistency matters more than intensity spikes
- •Top two pillars: diet and exercise (especially resistance training)
- •Caloric restriction can be beneficial in a metabolically unhealthy population
- •Additional pillars: stress optimization, sleep, sunlight/outdoors, and spiritual health
- 4:32 – 5:18
Diet as an individualized “fuel plan” + role of genetics and biofeedback
The conversation turns to diet, with an emphasis on individual variability. Dr. Gillett explains that genetics and subjective response can guide macronutrient strategy, and that genetic testing can help—but requires careful interpretation.
- •Diet should be individualized to goals, physiology, and genetics
- •Some people tolerate carbs/sugar better than others due to polymorphisms
- •Biofeedback can be a practical guide when formal testing isn’t available
- •Genetic testing may help but can be costly and needs expert interpretation
- 5:18 – 5:35
Bloodwork cadence: how often to test and why fasting vs. non-fasting matters
Huberman asks about routine lab frequency, and Dr. Gillett suggests a preventative testing cadence. He also distinguishes between fasting and non-fasting labs as complementary snapshots of metabolic and endocrine function.
- •Preventative bloodwork commonly every 3–6 months (context-dependent)
- •Include both fasting and non-fasting labs for a fuller picture
- •Testing supports course-correction of lifestyle and risk factors
- •Regular monitoring can detect trends before symptoms become severe
- 5:35 – 6:03
Exercise, Zone 2 cardio & the caloric restriction tradeoff
They discuss baseline exercise recommendations, especially Zone 2 cardio volume, and how it interacts with dietary restriction. Dr. Gillett frames exercise and caloric restriction as health-span tools more than scale-weight tools.
- •Zone 2 cardio targets ~150–180 minutes per week as a common baseline
- •More Zone 2 can reduce the need for prolonged caloric restriction
- •Exercise and restriction are primarily for health-span, not just weight change
- •Metabolic health status should guide how aggressive restriction should be
- 6:03 – 9:20
Caloric restriction vs. intermittent fasting: testosterone, growth hormone & IGF-1
Dr. Gillett clarifies that caloric restriction can raise testosterone in people with obesity/metabolic syndrome but may lower testosterone in young, healthy men. Intermittent fasting is framed as potentially supportive of growth hormone dynamics—especially with aging—provided total calories remain adequate.
- •In obesity/metabolic syndrome, restriction can improve testosterone
- •In young healthy men, restriction can reduce testosterone (evidence noted)
- •If calories are maintained, intermittent fasting is not inherently harmful to hormones
- •Fasting can increase growth hormone pulses; relevance may be greater in older adults
- •IGF-1 is discussed in terms of systemic (liver/endocrine) vs local (muscle/autocrine) effects
- 9:20 – 11:43
Hormones and sleep: GH deficiency, menopause/andropause symptoms & TRT-related sleep apnea
They examine hormone-related causes of sleep disruption, including early-morning waking. Dr. Gillett highlights three scenarios: true growth hormone deficiency, vasomotor symptoms tied to menopausal/andropausal shifts, and TRT increasing sleep apnea risk—especially in a dose-dependent manner.
- •True growth hormone deficiency can impair sleep; replacement can improve it
- •Menopause-related vasomotor symptoms can worsen sleep; similar patterns can occur in andropause
- •Low testosterone can contribute to poor sleep, but TRT can also worsen sleep via apnea risk
- •TRT may induce a hyper-sympathetic state early in treatment, affecting sleep quality
- •Sleep apnea risk rises with testosterone exposure even if starting levels were normal
- 11:43 – 13:33
Testosterone in women & SHBG: why ‘free’ vs total hormones change the story
Huberman probes misconceptions about testosterone in women. Dr. Gillett explains when testosterone is important for optimization versus when estrogen/progesterone are more critical for pathology prevention, and he details SHBG’s binding preferences and how unit differences confuse comparisons between hormones.
- •For women’s optimization, testosterone can be valuable; for breast cancer/osteoporosis prevention, estrogen/progesterone may be more central
- •Free testosterone is a small fraction; total levels can be more informative in context
- •SHBG strongly binds DHT, then testosterone, then weaker androgens, and least strongly estrogens
- •Women can have more total testosterone than estradiol depending on units used
- •DHEA is often present at higher levels than either testosterone or estradiol
- 13:33 – 16:47
DHT and androgen signaling: motivation, diet/supplements, and hair-loss tradeoffs
They unpack dihydrotestosterone (DHT) as a highly androgenic hormone acting through the androgen receptor (on the X chromosome). Diet and supplements can affect 5α-reductase activity (testosterone→DHT conversion), and they discuss hair-loss approaches that aim to localize DHT suppression to the scalp to reduce systemic side effects.
- •DHT is a potent androgen acting via the androgen receptor; receptor genetics matter
- •Androgen receptor gene is on the X chromosome (men inherit it from their mother)
- •Polyphenols can inhibit conversion of testosterone to DHT; examples include turmeric and black pepper extract
- •If DHT is already low or receptor sensitivity is low, highly bioavailable curcumin/piperine may be worth avoiding
- •Hair-loss strategy: reduce androgen receptor activity locally; example discussed is dutasteride mesotherapy (localized scalp injections)
- 16:47 – 20:13
PCOS: prevalence, diagnosis (Rotterdam), symptoms and treatment tools
Dr. Gillett provides a practical overview of polycystic ovarian syndrome (PCOS), emphasizing it’s underdiagnosed and often discovered during fertility struggles. He reviews diagnostic criteria and symptom clusters (androgen excess, insulin resistance, cycle irregularity) and outlines common interventions including body composition changes, metformin, and inositol variants.
- •PCOS may affect ~10–20% depending on criteria; often underdiagnosed
- •Common discovery occurs in the 30s, frequently via infertility/subfertility workups
- •Rotterdam criteria: androgen excess + insulin resistance and/or polycystic ovaries (ultrasound not always required)
- •Symptoms: hormonal acne, hirsutism, voice deepening, female-pattern hair loss, oligomenorrhea
- •Metabolic focus: improving insulin resistance and body composition can improve outcomes
- •Tools: metformin for insulin sensitization; myo-inositol (sensitizer) and D-chiro-inositol (mild anti-androgen) considerations
- 20:13 – 21:48
Cannabis, alcohol and testosterone: mechanisms and what matters most
They address conflicting claims about marijuana and testosterone. Dr. Gillett distinguishes cannabinoids from smoked marijuana’s effects (aromatase/estrogen changes), and notes that high alcohol and strong GABAergic drugs can reduce testosterone via endocrine suppression pathways.
- •THC/CBD alone aren’t framed as major direct testosterone suppressors
- •Smoked marijuana may increase aromatase → higher estradiol → downstream reductions in LH/FSH and testosterone
- •Endocrine feedback loops: higher estrogen can suppress gonadotropins
- •High alcohol intake decreases testosterone
- •Potent GABA agonists (barbiturates, benzodiazepines, alcohol) can lower testosterone
- 21:48 – 23:03
TRT and prostate cancer risk: initiation vs. growth of existing disease
They tackle a common fear: testosterone ‘causing’ prostate cancer. Dr. Gillett argues testosterone doesn’t initiate prostate cancer but can promote growth of existing cancer, which becomes more common with age—making individualized risk assessment and monitoring crucial.
- •Testosterone is framed as not causing prostate cancer de novo
- •Testosterone can grow existing prostate cancer once present
- •Age-related prevalence of occult prostate cancer rises sharply in older decades
- •TRT decisions should weigh aging-related risk and personal context
- •Emphasis on nuanced risk-benefit discussions rather than blanket rules
- 23:03 – 24:21
Prolactin, dopamine balance & dietary levers (casein/gluten)
Huberman and Dr. Gillett discuss prolactin’s relationship to dopamine and testosterone. Dr. Gillett uses the “dopamine wave pool” metaphor to argue for avoiding extreme dopamine spikes/crashes, and notes estrogen’s role in prolactin synthesis; he also suggests some people may trial removing casein or gluten to reduce prolactin-promoting signals.
- •Aim for stable dopamine dynamics; big spikes can lead to big crashes
- •Estrogen can upregulate prolactin gene expression, increasing prolactin
- •Higher prolactin can inhibit pituitary signaling that supports testosterone production
- •Dopamine agonists can reduce prolactin-producing cell activity in some contexts
- •Potential dietary lever discussed: eliminating casein and/or gluten (as gut mu-opioid receptor-active compounds)
- 24:21 – 26:21
Relationships, pheromonal/hormonal ‘crosstalk,’ and planning for life crises
They explore how close relationships can shape hormone and neurotransmitter patterns, including novelty, dopamine, and prolactin dynamics. Dr. Gillett encourages intentional planning—especially around major transitions like having children—anticipating shifts in prolactin, dopamine, and testosterone for both partners.
- •Close cohabitation can reduce novelty; periodic reprieve can restore excitement/dopamine responsiveness
- •Hormonal/pheromonal crosstalk can occur between partners
- •Pregnancy/breastfeeding periods may raise prolactin and lower dopamine/testosterone for both partners
- •Plan ahead for predictable relationship ‘crisis’ phases and protect high-quality time
- •Lifestyle/structure may matter as much as supplements in relationship resilience
- 26:21 – 34:04
Peptides overview: safety, growth hormone secretagogues, BPC-157 sourcing risks, melanotan uses
They give a safety-oriented primer on peptides, emphasizing heterogeneity, physician oversight, and FDA-approved vs non-approved uses. Discussion includes growth hormone peptides’ cancer/tumor risks, BPC-157’s VEGF-related concerns and the importance of clean compounding (avoiding LPS contamination), and melanotan/brimelanotide (PT-141) indications and melanoma caution.
- •Peptides range from life-saving (insulin) to risky; should be physician-directed
- •Growth hormone/GHRPs: potential benefits (lipolysis/body comp) vs serious risks (tumor growth/cancer)
- •BPC-157: may increase VEGF and blood flow—potentially helpful in poorly vascularized injuries but concerning in cancer risk contexts
- •Sourcing warning: non-medical suppliers may have LPS contamination; use reputable compounding pharmacies
- •Melanotan-related agents: FDA-approved uses include hypoactive sexual desire disorder (brimelanotide/PT-141) and other specific indications; caution with melanoma risk and need for skin checks
- 34:04 – 36:43
‘Spirit’ as a health pillar: integrating body, mind and meaning
They return to the sixth pillar—spiritual health—and how it fits in a medical context across belief systems. Dr. Gillett frames spirituality as an essential component interacting with mental and physical health, and argues for integrating disciplines rather than compartmentalizing care.
- •Spiritual health can influence physiology and mental well-being regardless of religious background
- •Venn diagram model: body, mind, and soul are interdependent
- •Patients often compartmentalize care; integration can improve outcomes
- •Interdisciplinary approaches within medicine support better results; broader integration may help further
- •Clinician’s role is to invite reflection without imposing beliefs
- 36:43 – 37:15
Caffeine and hormones: mostly indirect effects via sleep + closing remarks
In the wrap-up, Huberman asks whether caffeine meaningfully alters sex hormones. Dr. Gillett’s view is that caffeine’s primary hormonal relevance is indirect—if it disrupts sleep—otherwise effects are negligible; they then close the conversation.
- •Caffeine’s main endocrine impact is through sleep disruption
- •Mechanism referenced: adenosine antagonism
- •Other effects (e.g., minor allergy effects) are noted as negligible for hormone outcomes
- •Episode concludes with thanks and acknowledgements
